125 related articles for article (PubMed ID: 28304148)
1. The enigmatic role of RUNX1 in female-related cancers - current knowledge & future perspectives.
Riggio AI; Blyth K
FEBS J; 2017 Aug; 284(15):2345-2362. PubMed ID: 28304148
[TBL] [Abstract][Full Text] [Related]
2. RUNX1 prevents oestrogen-mediated AXIN1 suppression and β-catenin activation in ER-positive breast cancer.
Chimge NO; Little GH; Baniwal SK; Adisetiyo H; Xie Y; Zhang T; O'Laughlin A; Liu ZY; Ulrich P; Martin A; Mhawech-Fauceglia P; Ellis MJ; Tripathy D; Groshen S; Liang C; Li Z; Schones DE; Frenkel B
Nat Commun; 2016 Feb; 7():10751. PubMed ID: 26916619
[TBL] [Abstract][Full Text] [Related]
3. RUNX transcription factors at the interface of stem cells and cancer.
Deltcheva E; Nimmo R
Biochem J; 2017 May; 474(11):1755-1768. PubMed ID: 28490659
[TBL] [Abstract][Full Text] [Related]
4. Relationship between RUNX1 and AXIN1 in ER-negative versus ER-positive Breast Cancer.
Chimge NO; Ahmed-Alnassar S; Frenkel B
Cell Cycle; 2017 Feb; 16(4):312-318. PubMed ID: 28055379
[TBL] [Abstract][Full Text] [Related]
5. Defining a tissue stem cell-driven Runx1/Stat3 signalling axis in epithelial cancer.
Scheitz CJ; Lee TS; McDermitt DJ; Tumbar T
EMBO J; 2012 Nov; 31(21):4124-39. PubMed ID: 23034403
[TBL] [Abstract][Full Text] [Related]
6. RUNX1 and FOXP3 interplay regulates expression of breast cancer related genes.
Recouvreux MS; Grasso EN; Echeverria PC; Rocha-Viegas L; Castilla LH; Schere-Levy C; Tocci JM; Kordon EC; Rubinstein N
Oncotarget; 2016 Feb; 7(6):6552-65. PubMed ID: 26735887
[TBL] [Abstract][Full Text] [Related]
7. Runx1 is associated with breast cancer progression in MMTV-PyMT transgenic mice and its depletion in vitro inhibits migration and invasion.
Browne G; Taipaleenmäki H; Bishop NM; Madasu SC; Shaw LM; van Wijnen AJ; Stein JL; Stein GS; Lian JB
J Cell Physiol; 2015 Oct; 230(10):2522-32. PubMed ID: 25802202
[TBL] [Abstract][Full Text] [Related]
8. RUNX1 as a Novel Molecular Target for Breast Cancer.
Ariffin NS
Clin Breast Cancer; 2022 Aug; 22(6):499-506. PubMed ID: 35599145
[TBL] [Abstract][Full Text] [Related]
9. RUNX1-dependent mechanisms in biological control and dysregulation in cancer.
Hong D; Fritz AJ; Gordon JA; Tye CE; Boyd JR; Tracy KM; Frietze SE; Carr FE; Nickerson JA; Van Wijnen AJ; Imbalzano AN; Zaidi SK; Lian JB; Stein JL; Stein GS
J Cell Physiol; 2019 Jun; 234(6):8597-8609. PubMed ID: 30515788
[TBL] [Abstract][Full Text] [Related]
10. Expression status of RUNX1/AML1 in normal gastric epithelium and its mutational analysis in microdissected gastric cancer cells.
Usui T; Aoyagi K; Saeki N; Nakanishi Y; Kanai Y; Ohki M; Ogawa K; Yoshida T; Sasaki H
Int J Oncol; 2006 Oct; 29(4):779-84. PubMed ID: 16964375
[TBL] [Abstract][Full Text] [Related]
11. Intersection of FOXO- and RUNX1-mediated gene expression programs in single breast epithelial cells during morphogenesis and tumor progression.
Wang L; Brugge JS; Janes KA
Proc Natl Acad Sci U S A; 2011 Oct; 108(40):E803-12. PubMed ID: 21873240
[TBL] [Abstract][Full Text] [Related]
12. First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer.
Helms MW; Packeisen J; August C; Schittek B; Boecker W; Brandt BH; Buerger H
J Pathol; 2005 Jul; 206(3):366-76. PubMed ID: 15892165
[TBL] [Abstract][Full Text] [Related]
13. Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas.
Shedden KA; Kshirsagar MP; Schwartz DR; Wu R; Yu H; Misek DE; Hanash S; Katabuchi H; Ellenson LH; Fearon ER; Cho KR
Clin Cancer Res; 2005 Mar; 11(6):2123-31. PubMed ID: 15788657
[TBL] [Abstract][Full Text] [Related]
14. Expression of bmi-1 protein in cervical, breast and ovarian cancer.
Gavrilescu MM; Todosi AM; Aniţei MG; Filip B; Scripcariu V
Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1112-7. PubMed ID: 23700898
[TBL] [Abstract][Full Text] [Related]
15. Identification of tRNA-derived small RNA (tsRNA) responsive to the tumor suppressor, RUNX1, in breast cancer.
Farina NH; Scalia S; Adams CE; Hong D; Fritz AJ; Messier TL; Balatti V; Veneziano D; Lian JB; Croce CM; Stein GS; Stein JL
J Cell Physiol; 2020 Jun; 235(6):5318-5327. PubMed ID: 31919859
[TBL] [Abstract][Full Text] [Related]
16. Detection of pS2 messenger RNA in gynecological cancers.
Wysocki SJ; Hahnel E; Masters A; Smith V; McCartney AJ; Hahnel R
Cancer Res; 1990 Mar; 50(6):1800-2. PubMed ID: 2306733
[TBL] [Abstract][Full Text] [Related]
17. Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix.
Wu M; Gunning W; Ratnam M
Cancer Epidemiol Biomarkers Prev; 1999 Sep; 8(9):775-82. PubMed ID: 10498396
[TBL] [Abstract][Full Text] [Related]
18. Loss of
Bridges K; Yao HH; Nicol B
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430923
[TBL] [Abstract][Full Text] [Related]
19. Runx1 mediates the development of the granular convoluted tubules in the submandibular glands.
Ono Minagi H; Sarper SE; Kurosaka H; Kuremoto KI; Taniuchi I; Sakai T; Yamashiro T
PLoS One; 2017; 12(9):e0184395. PubMed ID: 28877240
[TBL] [Abstract][Full Text] [Related]
20. RUNX1 and cancer.
Lin TC
Biochim Biophys Acta Rev Cancer; 2022 May; 1877(3):188715. PubMed ID: 35271994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
